Novo Nordisk is known for manufacturing GLP-1 medications Ozempic and Wegovy.

“We look forward to working with the Omnicom team as we continue to scale consumer-focused strategies and connect with patients through emerging channels and technologies, helping bring even greater awareness of our medicines to people living with chronic conditions such as obesity and diabetes,” the spokesperson said.

The global account is valued at $618 million, with the U.S. account valued at $520 million, according to data from COMvergence.